CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for...
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and...
KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo genetic Alpha-1 Antitrypsin...
On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second half of 2024 Further strengthened...
Financing led by Deep Track Capital with participation from other leading healthcare investors Pro-forma cash and cash equivalents of approximately $236 million before fees and expenses On track for...
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial Officer,...
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the TD Cowen...
KRRO-110 has a potentially best-in-class profile with secretion of ~50µM functional AAT protein after a single dose in a preclinical mouse modelEvidence of greater than 40% editing of SERPINA1 RNA in...
CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the 42nd...